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Original ArticleIn Vivo PET Tracking of 89Zr-Labeled
Vg9Vd2 T Cells to Mouse Xenograft Breast Tumors
Activated with Liposomal Alendronate
Francis Man,1 Lindsay Lim,1 Alessia Volpe,1 Alberto Gabizon,2 Hilary Shmeeda,2 Benjamin Draper,3
Ana C. Parente-Pereira,3 John Maher,3 Philip J. Blower,1 Gilbert O. Fruhwirth,1 and Rafael T.M. de Rosales1
1School of Biomedical Engineering & Imaging Sciences, King’s College London, St Thomas’ Hospital, London SE1 7EH, UK; 2Oncology Institute, Shaare Zedek Medical
Center and Hebrew UniversitySchool of Medicine, Jerusalem 9103102, Israel; 3School of Cancer and Pharmaceutical Sciences, King’s College London, Guy’s Hospital,
London SE1 9RT, UKGammadelta T (gd-T) cells are strong candidates for adoptive
immunotherapy in oncology due to their cytotoxicity, ease of
expansion, and favorable safety proﬁle. The development of
gd-T cell therapies would beneﬁt from non-invasive cell-
tracking methods and increased targeting to tumor sites.
Here we report the use of [89Zr]Zr(oxinate)4 to track
Vg9Vd2 T cells in vivo by positron emission tomography
(PET). In vitro, we showed that 89Zr-labeled Vg9Vd2 T cells
retained their viability, proliferative capacity, and anti-cancer
cytotoxicity with minimal DNA damage for amounts of 89Zr
%20 mBq/cell. Using a mouse xenograft model of human
breast cancer, 89Zr-labeled gd-T cells were tracked by PET im-
aging over 1 week. To increase tumor antigen expression, the
mice were pre-treated with PEGylated liposomal alendronate.
Liposomal alendronate, but not placebo liposomes or non-
liposomal alendronate, signiﬁcantly increased the 89Zr signal
in the tumors, suggesting increased homing of gd-T cells to
the tumors. gd-T cell trafﬁcking to tumors occurred within
48 hr of administration. The presence of gd-T cells in tumors,
liver, and spleen was conﬁrmed by histology. Our results
demonstrate the suitability of [89Zr]Zr(oxinate)4 as a cell-la-
beling agent for therapeutic T cells and the potential beneﬁts
of liposomal bisphosphonate treatment before gd-T cell
administration.Received 5 June 2018; accepted 8 October 2018;
https://doi.org/10.1016/j.ymthe.2018.10.006.
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Adoptive transfer of therapeutic T cells is a growing ﬁeld in immuno-
oncology, with spectacular clinical results against melanoma and he-
matological cancers.1–3 Gammadelta-T (gd-T) cell therapy is one type
of T cell therapy being explored, with recent data showing intra-tu-
moral gd-T cells are the single most favorable prognostic immune
cell inﬁltrate.4 gd-T cells perform roles belonging to both adaptive
and innate immunity, playing a signiﬁcant role in anti-infectious
and anti-tumor immune surveillance.5 Activated gd-T cells are highly
cytotoxic, enhance the function of other immune cells, and act as an-
tigen-presenting cells.6 In humans, the Vg9Vd2 subtype of gd-T cells
represents 1%–5% of circulating CD3+ T cells.6 Their potent cytotox-Molec
This is an open access article under the CC BY-NC-icity and high proliferative capacity have made them candidates of
choice for cancer immunotherapy.7
The unique activation of Vg9Vd2 cells by phosphoantigens such as
isopentenyl pyrophosphate (IPP)8 allows them to discriminate be-
tween normal andmetabolically disordered cells based on IPP expres-
sion levels.9 The activation and targeting of gd-T cells to tumor tissue
could, therefore, be improved by selectively increasing the presenta-
tion of phosphoantigens in cancer cells, for example, by using
liposome- or nanocarrier-based formulations of aminobisphospho-
nate drugs (NBPs).10 NBPs (e.g., pamidronate, alendronate, and
zoledronate),11 which increase the expression of IPP in target cells
by inhibiting farnesyl diphosphate synthase, are hydrophilic mole-
cules that accumulate in bone, but not in other tissues, and are rapidly
cleared from the circulation. Encapsulating alendronate in liposomes
has been shown to increase the therapeutic efﬁcacy of gd-T cells in
preclinical models.12,13
Clinical studies of gd-T cell immunotherapy have shown a good
safety proﬁle and efﬁcacy comparable to second-line anticancer ther-
apies, but they have also highlighted the need for improvements.14,15
Unknown aspects of adoptive gd-T cell therapy include their in vivo
distribution and kinetics of arrival at the tumor site. Whole-body im-
aging is highly useful in this context by enabling in vivo tracking of
administered cells. Many techniques exist for non-invasive cell
tracking;16–18 however, only nuclear imaging, and particularly posi-
tron emission tomography (PET), provides sensitive and quantitative,
whole-body information with adequate spatiotemporal resolution.
Hence, methods to radiolabel and track therapeutic cells using posi-
tron-emitting radionuclides are likely to become important tools
for cell immunotherapy.19ular Therapy Vol. 27 No 1 January 2019 ª 2018 The Author(s). 219
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Radiotracer Synthesis and gd-T Cell
Radiolabeling
(A) [89Zr]Zr(oxinate)4 synthesis. (B) Labeling efficiencies
of gd-T cells incubated with 89Zr-based tracers (63.2 ±
7.9 mBq/cell) 20 min at RT. Mean of N = 3–4 individual
experiments (unpaired t test). (C) 89Zr retention by gd-T cells
over 7 days after labeling with [89Zr]Zr(oxinate)4 (average
incorporated activity: 34.3 ± 6.0 mBq/cell). Mean ± SEM of
triplicate measures for 3 cell batches.
Molecular TherapyPET tracking of T cells has been performed with radiolabeled anti-
bodies, antibody fragments, or lipophilic small molecules20,21 and
by reporter-gene imaging.22 When genetic engineering is not
required, e.g., for gd-T cells, a clinically applicable alternative to re-
porter-gene imaging is direct cell labeling with PET radionuclides.
Immune cells have long been imaged clinically by single-photon
emission computed tomography (SPECT) in this manner, for
example, using [111In]In(oxinate)3 and [
99mTc]Tc-exametazime.19
In this regard, the clinically approved 8-hydroxyquinoline (oxine)
has been recently shown to be an excellent ionophore for cell label-
ing with 89Zr (t1/2 = 78.4 hr, b
+ = 22.3%).23–25 However, to the best
of our knowledge, no study has evaluated its use for tracking gd-T
cells.
Here we report the ﬁrst use of [89Zr]Zr(oxinate)4 for in vitro radio-
labeling and in vivo tracking of human gd-T cells, including the
effects of radiolabeling on gd-T cell functionality, proliferation,
and DNA integrity. We applied this strategy in a xenograft model
of breast cancer with an engineered cancer cell line that allows
multimodal imaging to track tumor cells. A liposomal aminobi-
sphosphonate was administered to increase T cell trafﬁcking to
the tumor.
RESULTS
Radiotracer Labeling Efficiency and Retention in gd-T Cells
[89Zr]Zr(oxinate)4 was obtained by mixing neutralized
[89Zr]Zr(oxalate)4 with 8-hydroxyquinoline dissolved in chloro-
form (Figure 1A). The radiochemical yield was 77.6% ± 11.8%220 Molecular Therapy Vol. 27 No 1 January 2019(mean ± SD, N = 21), and radiochemical purity
established by thin-layer radiochromatography
was >95% (Figure S1). gd-T cell labeling efﬁciency
with [89Zr]Zr(oxinate)4 (46.6% ± 3.4%, N = 4) was
signiﬁcantly higher than with [89Zr]Zr(oxalate)4
(6.5% ± 1.1%, N = 3; Figure 1B). To optimize ra-
diolabeling conditions, cells were incubated with
[89Zr]Zr(oxinate)4 (6600 mBq/cell) for 10, 20,
or 30 min at 4C, room temperature (RT),
or 37C. We found no signiﬁcant difference
between incubation times and temperatures
(Figure S2).
To study long-term tracer retention, radiolabeled
gd-T cells (2540 mBq/cell) were cultured at0.83  106 cells/mL. After 24 hr, the percentage of cell-associated
89Zr was 72.9% ± 6.8% of the original activity, and 42.4% ± 12.6% af-
ter 1 week (N = 3; Figure 1C).
In Vitro Assays of 89Zr-Radiolabeled gd-T Cells
The purity of in vitro-expanded gd-T cells plateaued 1315 days
post-isolation (Figure S3), at which point they were radiolabeled.
Cells labeled with 620 mBq/cell proliferated similarly to unlabeled
cells (p R 0.05; Figure 2A), while cells labeled with more than
50mBq/cell ceased to proliferate in vitro, indicating a dose-dependent
effect of 89Zr on gd-T cell proliferation. A similar dose dependency
was observed on gd-T cell death (Figure 2B) and DNA damage, eval-
uated by the formation of gH2AX foci26 1 hr after labeling (Figures
2C and 2D).
To evaluate the cytotoxic ability of radiolabeled gd-T cells, we
quantiﬁed the survival of MDA-MB-231.hNIS-GFP cancer cell
monolayers. gd-T cells labeled with up to 600 mBq/cell showed
no signiﬁcant difference in cancer cell killing compared to unla-
beled gd-T cells (Figure 2E). As a control, adding 89Zr up to 3
Bq/cancer cell in the medium was not toxic to cancer cells in the
absence of gd-T cells. Even in 30-fold excess, gd-T cells showed
no toxicity toward cancer cells in the absence of aminobisphosph-
onate (Figure S4).
In Vivo PET Tracking of 89Zr-Radiolabeled gd-T Cells
89Zr-radiolabeled gd-T cells were administered intravenously in a
mouse xenograft model of breast cancer followed by PET imaging
Figure 2. Assays of 89Zr-Radiolabeled gd-T Cells
(A andB) In vitrogrowth (A) andmortality (B) of radiolabeledgd-T cells.Mean±SEMofN=4 independent experiments (except 150–450mBqgroup,N=2,not included in statistical
analysis). ns: p > 0.05; ****p < 0.0001 versus unlabeled cells (2-way repeated-measures ANOVA, Dunnett’s correction for multiple comparisons). (C) Representative images of
g-H2AX foci (green) andnuclei (blue) in radiolabeledgd-Tcells (scalebars, 10mm). (D)Averagenumberofg-H2AX fociper nuclei after radiolabeling.Mean±SEMofN=6,5,6,and3
independent experiments (1-way ANOVA, Dunnett’s correction). (E) MDA-MB-231.hNIS-GFP tumor cell viability 48 hr after adding gd-T cells or unchelated 89Zr, expressed as a
percentage of control (tumor cells without gd-T cells and 89Zr). Mean ± SEM of N = 3 independent experiments (2-way repeated-measures ANOVA, Dunnett’s correction).
www.moleculartherapy.orgat 1 hr, 48 hr, and 7 days after injection.We imaged the hNIS-express-
ing cancer cells by SPECT using 99mTcO4
.27 We also evaluated the
effect of PLA on gd-T cell homing to tumor sites. The study schedule
is provided in Figure 3A.The PLA dosing schedule was established using 111In-labeled PLA,
showing signiﬁcant PLA tumor accumulation within 24–72 hr of
administration (Figure 3B; Table S1). The experimental group (PLA
treated) received radiolabeled gd-T cells + PLA (5 mg/kg alendronate).Molecular Therapy Vol. 27 No 1 January 2019 221
(legend on next page)
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Figure 4. PLA Treatment Increases the Accumulation
of gd-T Cells in Tumors
(A) Ex vivo bio-distribution of radiolabeled gd-T cells, 7 days
after gd-T cell administration. Mean ± SEM of 89Zr uptake
after PLA (N = 6 and 3, respectively), placebo liposomes
(N = 4), non-liposomal alendronate (ALD; N = 3), or vehicle
(N = 5) treatment. Data are from 3 pooled independent
experiments (total N = 21). (B) Comparison of 89Zr accu-
mulation in the tumor between PLA (N = 9) and non-PLA
(N = 12) treatments (unpaired t test). (C) Artificially colored
autoradiographs of tumor sections after PLA, placebo li-
posomes or non-liposomal alendronate (ALD) treatment.
Images are representative of N = 3, 4, and 3 animals per
group (scale bar, 10 mm).
www.moleculartherapy.orgControl groups (non-PLA treated) received radiolabeledgd-T cellswith
placebo liposomes, non-liposomal alendronate, or saline. An additional
control group received gd-T cells killed by freeze-thawing to compare
bio-distributions of viable and non-viable cells.
SPECT showed uptake of 99mTcO4
 in tumors and endogenous NIS-
expressing organs (thyroid, salivary, and lacrimal glands and stomach;
Figure 3C). At 1 hr after intravenous administration of 89Zr-radiola-
beled gd-T cells, PET revealed high amounts of radioactivity in the
lungs in all groups, with signal also observed in the liver and spleen
(Figures 3C and 3D). There was signiﬁcantly higher uptake in the liver
in the ALD group versus the PLA group. At tumor sites, the 89Zr signal
was close to background (Figure S5). After 48 hr, 89Zr activity increased
in the liver, spleen, and bones in all groups and decreased in the lungs.
Uptake of 89Zr was observed at the tumor site only in the PLA group
(Figure S5), suggesting the presence of radiolabeled gd-T cells. Impor-
tantly, this was signiﬁcantly higher in PLA-treated animals compared
to control animals treatedwith non-liposomal alendronate (Figure 3D).
Enlarged tumor views showed heterogeneity in tumor tissue, with live
tissue, expressing a functional hNIS protein18,27 and represented by a
donut of 99mTc signal surrounding a core of non-viable tumor cellsFigure 3. In Vivo Tracking of Radiolabeled gd-T Cells
(A) Experiment schedule. (B) Representative SPECT-CT images of MDA-MB-231.hNIS-GFP xenograft NSG m
Representative PET, SPECT, and CT (merged) scans of a PLA-treated SCID/beige mouse at 1, 48, and 168 hr
T, tumor. Endogenous murine NIS expression also results in radiotracer uptake, giving rise to the following sign
salivary glands. (D) Time-activity curves from image-based quantification of 89Zr in selected organs. Mean ± S
Bonferroni correction for multiple comparisons). (E) Enlarged maximum intensity projection (MIP), coronal, sagitt
CT) in three PLA-treated mice (M1, M2, and M3), 48 hr after gd-T cell injection.
Mol(Figure 3E). 89Zr signal in tumors was heteroge-
neous, with some co-localizing with 99mTc at the
edges and foci of 89Zr signal inside the tumor. Af-
ter 7 days, 89Zr activity remained high in the liver;
increased in the spleen, bones, and kidneys; and
was indistinguishable from background in
tumors. Uptake values are provided in Table S2.
Compared to other treatment groups, PET
images of killed gd-T cells showed a higher
accumulation in the liver immediately after injec-tion and increased uptake of 89Zr in the kidneys at later time
points (Figure S6).
Ex Vivo Bio-distribution of 89Zr-Radiolabeled gd-T Cells
Ex vivo g-counting 7 days post-administration of radiolabeled cells re-
vealed a high concentration of 89Zr in the spleen (153.5% ± 88.8% in-
jected dose [ID]/g averaged across all groups, N = 24) and liver
(58.1% ± 10.6% ID/g, N = 24) in all groups, followed by lung and
bone tissue (Figure 4A). Uptake of 89Zr in tumors from PLA-treated
groups (2.1% ± 0.8% ID/g) was signiﬁcantly higher than in non-PLA
groups (1.2% ± 0.3% ID/g; Figure 4B), suggesting higher gd-T cell
numbers in PLA-treated tumors. Bone uptake of 89Zr in PLA-treated
groups (6.5% ± 0.8% ID/g, N = 9) was signiﬁcantly lower than in other
groups (10.0%± 1.1% ID/g, N = 12; p = 0.0238). Uptake in kidneys was
signiﬁcantlyhigherwithkilledgd-Tcells than inother treatment groups
(Table S3). Uptake in other organs showed no major differences be-
tween treatment groups.
Tumor section autoradiographs showed a strong signal originating
from hNIS-accumulated 99mTcO4
. Autoradiography was repeated
after 4 days to allow for the decay of 99mTc and the capture 89Zr signal.ice 24 and 72 hr after 111In-labeled PLA administration. (C)
post-injection of gd-T cells. Liv, liver; Lu, lungs; Sp, spleen;
als: La, lacrimal glands; St, stomach; and Thy/Sal, thyroid/
EM of N = 3–4 animals (repeated-measures MM analysis,
al, and transversal tumor views (merged PET- and SPECT-
ecular Therapy Vol. 27 No 1 January 2019 223
Figure 5. Histology of gd-T Cells
(A–C) Tumor sections 48 hr (A and C) or 7 days (B) after the injection of 89Zr-radiolabeled gd-T cells into mice treated with PLA (A and B) or without PLA (C), stained for human
CD3 (gd-T cells) or GFP (tumor cells). Arrows indicate representative CD3+ cells. (D) Spleen, liver, and kidney sections 7 days after the administration of 89Zr-radiolabeled gd-T
cells. Sections are representative of N = 2–3 animals per time point. 6 (left) and 30 (right) magnification; scale bars, 500 mm (left) and 50 mm (right).
Molecular TherapySections from PLA-treated animals showed increased 89Zr signal
compared to non-PLA-treated animals. The 89Zr signal was higher
in the tumor periphery, whereas the 99mTc signal was uniformly
distributed (Figure 4C). gd-T cell presence in tumors was demon-
strated by immunohistochemistry. Human CD3-positive cells
(>95% gd-T cell receptor [TCR]+ at the time of administration; Fig-
ure S3) were visible in tumors 48 hr and 7 days after injection, both in
the periphery and deeper regions (Figures 5A–5C; Figure S7). These
cells were also visible in the spleen and liver after 7 days, but not in
kidney sections (Figure 5D) or in control tissues of mice not admin-
istered gd-T cells (Figure S8).
DISCUSSION
[89Zr]Zr(oxinate)4 synthesis has been reported previously by our
group23 and others.24,25 The temperature-independent labeling efﬁ-
ciency of gd-T cells with [89Zr]Zr(oxinate)4 suggests this is a passive
process, in line with results from Sato et al.24 Sufﬁcient radiotracer
retention within cells is important to ensure that the imaging signal224 Molecular Therapy Vol. 27 No 1 January 2019reﬂects labeled cells rather than free radiotracer bio-distribution.
We observed an efﬂux of approximately half of the incorporated
89Zr over 1 week in vitro, which we believe does not interfere with
in vivo imaging within this time frame. Uptake of 89Zr in the bone
can be used to estimate the amount of tracer that leaked from the
cells.25,28 Retention of [89Zr]Zr(oxinate)4 is dependent on cell type,
and our results are comparable to those observed with dendritic,
bone marrow, and chimeric antigen receptor (CAR)-T cells.23–25
Comparable levels of tracer efﬂux have been observed from lympho-
cytes labeled with [111In]In(oxinate)3,
29,30 the current gold standard
for cell tracking by nuclear imaging.
A radiotracer for cell tracking must not signiﬁcantly alter the pheno-
type, survival, proliferation capacity, and functionality of labeled
cells. We demonstrated that the effects of [89Zr]Zr(oxinate)4 on
gd-T cell survival, proliferation capacity, and DNA damage were
kept minimal for doses up to 20 mBq/cell but were signiﬁcant at
doses R50 mBq/cell. The cytotoxicity of radiolabeled gd-T cells
www.moleculartherapy.orgagainst the same tumor cells used for in vivo experiments was not
affected by amounts of [89Zr]Zr(oxinate)4 of up to 600 mBq/cell,
at least within 48 hr of radiolabeling. Cancer cell death was due to
the combination of bisphosphonate treatment and gd-T cells and
not to the presence of 89Zr. Preserved cytotoxicity after radiolabel-
ing, also recently observed in CAR-T cells byWeist et al.,25 is encour-
aging for the use of [89Zr]Zr(oxinate)4 as a T cell-tracking agent.
However, the therapeutic efﬁcacy of gd-T cells presumably also re-
lies on their in vivo proliferation ability; hence, we suggest that radio-
labeling gd-T cells with [89Zr]Zr(oxinate)4 should ideally not exceed
20 mBq/cell. This could lead to sensitivity issues on conventional
PET scanners. Indeed, our experiments show that ex vivo gamma-
counting tumors could reveal amounts of 89Zr indistinguishable
from background in our PET imaging system at day 7. Assuming
that a human cell-tracking study would require 37 MBq 89Zr31 and
109 gd-T cells,14 this would equate to an average of 37 mBq/cell,
which we have shown not to be excessively damaging to gd-T cells.
Upcoming developments in PET technology, such as total-body
PET,32 should reduce the required 89Zr activity per cell (by a factor
of 40) and overcome these sensitivity issues.
For in vivo studies, a xenograft model of human breast cancer in
immunocompromised mice12,33 was chosen, as mice do not possess
a subset of T cells functionally equivalent to human Vg9Vd2
T cells.34 We tracked gd-T cells radiolabeled with [89Zr]Zr(oxinate)4
(30300 mBq/cell) by PET 1 hr, 48 hr, and 7 days after intravenous
injection. We simultaneously used 99mTcO4
 to visualize hNIS-ex-
pressing tumors by SPECT. The in vivo distribution of 89Zr-labeled
gd-T cells over time was similar to that observed in studies of adop-
tively transferred gd-T35,36 and other T cells.25,37,38 89Zr uptake was
signiﬁcantly increased in PLA-treated tumors, suggesting that PLA
increases homing of these cells to the tumor site. Accumulation of
gd-T cells at the tumor site 48 hr after administration was also
observed by others.35 Uptake values for the spleen and tumor deter-
mined by image-based quantiﬁcation are lower than those deter-
mined by ex vivo bio-distribution. This can be explained by the small
size of this organ and signiﬁcant partial volume effect (spleen) and the
liquid or necrotic tumor core that leaked upon dissection.
For instrument sensitivity reasons, some imaging studies were per-
formed with higher doses of 89Zr than recommended above. How-
ever, the distinctly different distribution pattern observed with killed
gd-T cells suggests that radiolabeling with up to 300 mBq/cell, which
preserved cytotoxic functionality in vitro over 48 hr, did not impair
gd-T cell trafﬁcking and allowed us to track live cells. Furthermore,
previous studies have shown that [89Zr]Zr(oxalate)4,
28,39 [89Zr]
Zr(oxinate)4, and lysates from [
89Zr]Zr(oxinate)4-labeled cells
23
have distinct distribution patterns from intact cells labeled with
[89Zr]Zr(oxinate)4. Cell concentrations during labeling and in vitro
assays were in the range of 15  106/mL. In comparison, using
in vitro 89Zr retention values, cell concentrations extrapolated from
PET-computed tomography (CT) images in the organs showing the
strongest 89Zr signal (spleen, liver, and lungs) would be in the range
of 0.55  106 cells/mL. We therefore expect the DNA damage sus-tained by gd-T cells, due to both self-irradiation and crossﬁre, after
in vivo administration to be comparable to that observed in vitro.
Considering the strong afﬁnity of the 89Zr4+ ion for bone,28 the rela-
tively low bone accumulation of 89Zr indicates limited efﬂux of weakly
chelated 89Zr, and it suggests that 89Zr is mostly retained by gd-T cells
after injection. The lower accumulation of 89Zr in the bones of PLA-
treated animals compared to other groups also suggests reduced efﬂux
of 89Zr from gd-T cells after PLA treatment.
Histology conﬁrmed the presence of gd-T cells in the tumors, spleen,
and liver, using the CD3 marker.40 Immunohistochemistry and
autoradiography suggest that gd-T cells accumulated mostly at the
periphery of the tumor. The small number of cells observed by immu-
nohistochemistry precludes statistical comparison. Furthermore,
these techniques can only image the solid portion of the tumor.
PET imaging not only allowed visualization of the whole, intact tu-
mors but additionally revealed heterogeneous distributions of 89Zr
in tumors, which would be challenging to observe by histology. Com-
bined with the non-invasive nature of PET imaging, this further high-
lights the value of using PET tracers such as [89Zr]Zr(oxinate)4 for cell
tracking. The high uptake of 89Zr in the liver and spleen was mirrored
by the large numbers of human CD3+ cells observed in these tissues,
consistent with the bio-distribution of radiolabeled gd-T cells. In
contrast, the apparent absence of CD3+ cells in the kidneys, despite
higher 89Zr uptake than in the tumor, and the fact that the kidney up-
take of 89Zr was signiﬁcantly higher in animals administered killed
gd-T cells than in other groups both suggest that the radioactivity de-
tected in the kidneys corresponds to 89Zr progressively released from
gd-T cells in other organs. A limitation of directly labeling cells is that
the radionuclide can leak out over time and be taken up by adjacent
tissue. Although immunohistochemistry demonstrates the presence
of the administered gd-T cells in the tumors, this technique cannot
determine whether the 89Zr signal originates from the gd-T cells or
from in situ-labeled bystander cells.
A critical aspect of this type of cellular immunotherapy is that the
therapeutic cells must be activated at the target site and reach the tu-
mor in sufﬁcient numbers. gd-T cell toxicity toward cancer cells is
greatly ampliﬁed by bisphosphonates, suggesting a role for gd-T cells
in the anti-cancer properties of bisphosphonates.41 Here we sought to
increase phosphoantigen expression in tumors by administering PLA,
which delivers alendronate to the tumors in an untargeted fashion by
virtue of the enhanced permeability and retention (EPR) effect.42
Liposomal alendronate proved safer than other bisphosphonates
and effective in potentiating gd-T cell therapy.12,43 We have previ-
ously shown that the tumor-to-background uptake ratio of PLA in-
creases over time and is signiﬁcant after 3 days.44 Here we observed
that PLA administered 4 days in advance signiﬁcantly increased the
amount of 89Zr reaching the tumor within 48 hr of radiolabeled
gd-T cell administration. Our results suggest that gd-T cells home
to the tumor within 2 days and remain there for at least 5 days.
This was not observed in any other treatment group, demonstrating
the importance of encapsulating the aminobisphosphonate in a tu-
mor-targeting vehicle.Molecular Therapy Vol. 27 No 1 January 2019 225
Molecular TherapyClinical imaging studies of therapeutic T cells with [111In]In
(oxinate)3 have been performed by radiolabeling only a fraction of
the total administered T cells,45–47 although evidence exists that
distributing the total activity over a larger number of cells better pre-
serves their proliferative abilities.48 Our results suggest that radiolab-
eling the entire batch of gd-T cells with [89Zr]Zr(oxinate)4 might be
the preferable option to avoid imaging excessively damaged cells. In
two notable studies, g-scintigraphy revealed T cell uptake in
tumors using only 13 mBq 111In per cell.46,49 Considering the
increased sensitivity of PET over SPECT and expected improve-
ments in PET technology, clinical imaging of T cell therapies using
[89Zr]Zr(oxinate)4 is a credible prospect.
Conclusions
This study demonstrates the suitability of [89Zr]Zr(oxinate)4 as a PET
tracer to track gd-T cells in vivo, while previous work has shown the
therapeutic efﬁcacy of gd-T cells in combination with PLA.12,43 These
objectives achieved, [89Zr]Zr(oxinate)4 can now be applied to answer
fundamental questions in the preclinical and clinical development of
gd-T cell therapies, e.g., whether the accumulation of gd-T cells at the
tumor site or their distribution within the tumor correlates with ther-
apeutic efﬁcacy. Due to numerous molecular and cellular differences,
the distribution of human gd-T cells in an immunocompromised
mouse model cannot fully predict their behavior in a human host.
However, the results of this proof-of-principle study can be used to
design a clinical trial that will answer the question of the distribution
of gd-T cells in humans after adoptive transfer.
Our results have implications for clinical translation, and they suggest
using liposomal aminobisphosphonates as adjuncts to gd-T cell ther-
apy. In the context of clinical protocols involving repeated infusions
of gd-T cells,15 one can envisage the use of 89Zr-labeled cells for the
ﬁrst infusion, followed by PET imaging 24–72 hr later. The number
of cells trafﬁcking to the tumor sites would then be used to decide
whether to pursue with additional treatment cycles. Cell radio-
labeling with [89Zr]Zr(oxinate)4 is clinically translatable without
signiﬁcant methodological modiﬁcations, and the high similarity of
[89Zr]Zr(oxinate)4 to the well-established [
111In]In(oxinate)3 should
facilitate regulatory approval. Our results support that T cell labeling
with [89Zr]Zr(oxinate)4 is a realistic option for human studies and will
beneﬁt the development of cellular immunotherapy.
MATERIALS AND METHODS
Experiment Approval
Animals experiments were approved by the UK Home Ofﬁce under
The Animals (Scientiﬁc Procedures) Act (1986), PPL reference
7008879 (Protocol 6), with local approval from King’s College Lon-
don Research Ethics Committee (KCL-REC). Experiments using
human T cells received approval from KCL-REC (Study Reference
HR-16/17-3746). All donors provided written, informed consent.
Reagents, Animals, and Cells
Unless otherwise indicated, reagents were purchased from Sigma-Al-
drich andMerck. Female SCID/beige (CB17.Cg-PrkdcscidLystbg-J/Crl)226 Molecular Therapy Vol. 27 No 1 January 2019and Nod scid gamma (NSG) (NOD.Cg-Prkdcscid Il2rgtm1WjI/SzJ)
mice (1825 g, 1020 weeks old) were obtained from Charles River
(UK). gd-T cells were obtained as described previously,12 using zo-
ledronate (Novartis) and interleukin-2 (IL-2) (Novartis). Full details
are provided in the Supplemental Materials and Methods. Population
purity was assessed by ﬂow cytometry (BD FACSCalibur), using
pan-gd TCR (IMMU510, Beckman Coulter B49175) and anti-CD3
(OKT3, BioLegend 317307) monoclonal antibodies. Data were
analyzed using Flowing version (v.)2.5.1 (http://ﬂowingsoftware.btk.
ﬁ). Only batches with R80% gd-positive CD3+ cells were used for
further experiments (R95% for in vivo experiments). MDA-MB-
231.hNIS-GFP cells27 were grown in DMEM supplemented with
10% fetal bovine serum (FBS), penicillin, streptomycin, and L-gluta-
mine (2 mM), and they were tested for mycoplasma contamination
(e-Myco PCR detection kit, Bulldog Bio).PET Tracer Synthesis
[89Zr]Zr(oxinate)4 was synthesized as previously described.
23 Full de-
tails are provided in the Supplemental Materials and Methods.Cell Labeling
gd-T cells expanded in vitro12 were washed with PBS (Ca2+/Mg2+
free) and re-suspended at 5  106/mL in PBS at RT. [89Zr]Zr
(oxinate)4 (6600 mBq/cell) in aqueous DMSO was added to the
cell suspension, keeping DMSO concentrations%0.7%. Neutralized
[89Zr]Zr(oxalate)4 with an equivalent amount of DMSO was used
as a control. After 1030 min of incubation, cells were pelleted and
the supernatants kept aside. The cells were washed with PBS, centri-
fuged, and the washings combined with the previous supernatants.
The cells were suspended in growthmedium or PBS for further exper-
iments. Viability was assessed using the trypan blue dye exclusion
method. Radioactivity in re-suspended cells and combined superna-
tants was measured in a gamma-counter. Cell-labeling efﬁciency
(LE[%]) was calculated as follows.
LEð%Þ= activity of cell fraction
activity of cell fraction + activity of combined supernatants
For radiotracer retention and cell proliferation studies, radiolabeled
(or vehicle-treated) gd-T cells were cultured as described above,
and they were analyzed at various time points for viability (using try-
pan blue), determination of cell-associated radioactivity (by g-count-
ing), and cell death (by ﬂow cytometry using propidium iodide [PI];
Thermo Scientiﬁc). Further details are provided in the Supplemental
Materials and Methods.
Cancer Cell-Killing Assay
MDA-MB-231.hNIS-GFP cells seeded in a 96-well plate at 104 cells/
well and incubated overnight were treated with 3 mM zoledronate or
vehicle for 24 hr. The cells were washed and the medium was replaced
with gd-T cells in growth medium. As a control for radiolabeled gd-T
cells, an equal amount of 89Zr in medium was added to some wells.
After 48 hr, gd-T cells were removed by washing with PBS, and cancer
cell viability was evaluated using the alamarBlue assay (Thermo
www.moleculartherapy.orgScientiﬁc), reading plates in a GloMax (Promega) reader (530 nm
excitation and 590 nm emission ﬁlters).
Determination of DNA Double-Strand Breaks
Radiolabeled gd-T cells in medium were seeded onto poly-L-lysine-
coated coverslips and incubated for 1 hr. After centrifugation and
gentle rinsing with PBS, the cells were ﬁxed and permeabilized with
3.7% formalin, 0.5% Triton X-100, and 0.5% IGEPAL CA-630 in
PBS, then blocked with 2% BSA and 1% goat serum. gH2AX foci
were detected with an anti-gH2AX (Ser139) mouse monoclonal anti-
body (mAb) (1:1,600; JBW301, Merck 05-636) and goat anti-mouse
AF488-immunoglobulin G (IgG) (1:500; Jackson ImmunoResearch
Laboratories 115-545-062). Nuclei were detected with Hoechst
33342. Images were acquired on a TCS SP5 II confocal microscope
(Leica) with a 100/1.40 HCX PL Apochromat objective (Leica)
and Leica Application Suite Advanced Fluorescence (LAS-AF) con-
trol software. Ten sections (0.4-mm thickness) were imaged. At least
30 nuclei/slide were imaged (2 slides/treatment). Maximal intensity
projections of z stacks were made using ImageJ v.1.51p (https://
imagej.nih.gov/ij/). Nuclei and gH2AX foci were counted using Cell-
Proﬁler v.2.2.0 (http://cellproﬁler.org), calculating average numbers
of gH2AX foci per nucleus in each image. Full details are provided
in the Supplemental Materials and Methods.
Animals, Tumor Model, and Tumor Sensitization with Liposomal
Alendronate
Approximately 1.5 106MDA-MB-231.hNIS-GFP cells were injected
subcutaneously in the mammary fat pad between the fourth and ﬁfth
nipples in the left ﬂank; tumors were grown over 3 weeks. Animals
were randomly assigned to experimental groups, and investigators
were not blinded to cohort allocation when assessing outcomes.
Cohort sizes were chosen based on prior experience,44,50 in compliance
with local regulations concerning animal experiments. Liposomal
formulations were prepared at Shaare Zedek MC as previously
described.13 Alendronate-loaded liposomes (PLA) contained
1.55.4 mg/mL alendronate and 3640 mmol/mL phospholipids. Pla-
cebo liposomes contained 2050 mmol/mL phospholipids. PLA was
co-injected with placebo liposomes for a total dose of 5 mg/kg alendr-
onate and 4 mmol phospholipids per mouse in PLA-treated animals.
Placebo-treated animals received empty liposomes corresponding to
4 mmol phospholipids per mouse. Another control group received
5mg/kg alendronate (ALD). Formulations were injected intravenously
(i.v.) 4 days before the administration of radiolabeled gd-T cells.
In Vivo PET and SPECT Imaging of gd-T Cells, Tumors, and PLA
89Zr-radiolabeled gd-T cells (107 cells/animal in 100 mL, 0.33 MBq
89Zr, single gd-T donor per experiment) were injected i.v. at t = 0 hr
and imaged by PET/CT within 30 min. PET/CT imaging was per-
formed for 30240 min (as indicated) on a nanoScan PET-CT scan-
ner (Mediso). For tumor imaging, 100 mL 99mTcO4
 (1525 MBq) in
saline was injected i.v., and SPECT-CT was performed 40 min there-
after in a NanoSPECT/CT scanner (Mediso; 1-mm collimators,
30-min scan). PET-CT and SPECT-CT were repeated at t = 48 and
168 hr. For PLA imaging by SPECT-CT, PLA was radiolabeled with[111In]In(oxinate)3 and administered i.v. (7 MBq
111In/mouse) to
NSG mice. PET- and SPECT-CT datasets were reconstructed using
a Monte Carlo-based full-3D iterative algorithm (Tera-Tomo, Med-
iso). Images were co-registered and analyzed using VivoQuant
v.2.50 (Invicro). Regions of interest (ROIs) were delineated for PET
activity quantiﬁcation in speciﬁc organs. Uptake in each ROI was ex-
pressed as a percentage of injected dose per volume (% ID/mL).
Ex Vivo Bio-distribution Studies
Mice from imaging studies were used for bio-distribution studies on
day 2 or 7. After culling, organs were dissected, weighed, and
g-counted together with standards prepared from a sample of injected
material. The percentage of injected dose per gram (% ID/g) of tissue
was calculated. Organs were cryopreserved in optimal cutting temper-
ature (OCT) compound (VWR) for autoradiography and/or formalin
ﬁxed and parafﬁn embedded (FFPE) for histologic analysis.
Autoradiography
Cryopreserved tissues were cut (50 mm), mounted on poly-L-lysine-
coated slides (VWR), ﬁxed in 4% paraformaldehyde (PFA), mounted
in Mowiol, and exposed to a storage phosphor screen for 20 min at
3 hr post-dissection to obtain the 99mTc signal, then for 48 hr at
4 days post-dissection to obtain the 89Zr signal. The storage phosphor
screen was read using a Cyclone Plus imager (PerkinElmer), and im-
ages were processed with ImageJ.
Immunohistochemistry
Brieﬂy, FFPE organ blocks were sliced and stained using a Discovery
XT system (Ventana Medical Systems) using the DAB Map detection
kit (Ventana 760-124). For pre-treatment, CC1 (Ventana 950-124)
was used. Sections were stained with anti-GFP (1/1,000; Abcam
ab290, UK) or anti-CD3 (LN10, Leica CD3-565-L-CE) primary anti-
bodies, followed by biotinylated anti-rabbit or anti-mouse IgG (1/200;
Dako) secondary antibodies, as appropriate. Full details are provided
in the Supplemental Materials and Methods.
Statistics
Independent experiments were performed on different days with
gd-T cell batches from different donors. Data were plotted using
Prism v.7.01 (GraphPad). Differences between 2 groups were evalu-
ated by Student’s two-tailed t test. To account for repeated measure-
ments in a same animal or cell batch and multiple treatments tested
on a same cell batch, analysis was performed using 2-way repeated-
measures ANOVA in GraphPad Prism or a repeated-measures Mixed
Model (MM)51 in InVivoStat v.3.7 (http://invivostat.co.uk/), as indi-
cated. Dunnett’s post hoc test was applied for comparisons back to a
control group, or Bonferroni correction for multiple pairwise com-
parisons, unless otherwise speciﬁed. Exact signiﬁcance values are re-
ported in each ﬁgure.
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